Symbols / PBLA $0.01 -14.94% Panbela Therapeutics, Inc.
PBLA Chart
About
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Stock Fundamentals
Scroll to Statements| Market Cap | 53.89K | Enterprise Value | 1.72M | Income | -37.05M | Sales | — | Book/sh | -3.74 | Cash/sh | 0.97 |
| Dividend Yield | — | Payout | 0.00% | Employees | 7 | IPO | — | P/E | — | Forward P/E | -0.00 |
| PEG | — | P/S | — | P/B | -0.00 | P/C | — | EV/EBITDA | — | EV/Sales | — |
| Quick Ratio | 0.25 | Current Ratio | 0.26 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -34.51 | EPS next Y | -5.66 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2025-07-23 | ROA | -229.77% | ROE | — | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.85M | Shs Float | 4.85M | Short Float | 3.07% |
| Short Ratio | 0.07 | Short Interest | — | 52W High | 2.50 | 52W Low | 0.00 | Beta | 1.88 | Avg Volume | 1.08K |
| Volume | 1.01K | Target Price | — | Recom | None | Prev Close | $0.01 | Price | $0.01 | Change | -14.94% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.01
Latest analyst target
3. DCF / Fair value
$-29.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-08-15 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-06-24 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-05-16 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-03-27 | main | Roth MKM | Buy → Buy | $25 |
| 2024-02-05 | main | Roth MKM | Buy → Buy | $25 |
- Panbela Therapeutics (PBLA) Stock Price, News & Analysis - MarketBeat Wed, 21 Jan 2026 14
- PBLA Stock Price and Chart — OTC:PBLA - TradingView Sat, 09 Mar 2024 14
- Panbela Therapeutics Stock Price Forecast. Should You Buy PBLA? - StockInvest.us Fri, 12 Feb 2021 14
- Panbela Therapeutics Inc (PBLA) Quarterly 10-Q Report - qz.com hu, 14 Nov 2024 08
- Panbela Provides Business Update and Reports Q3 2024 Financial Results - GlobeNewswire hu, 14 Nov 2024 08
- Nasdaq to delist Panbela Therapeutics over equity shortfall - Investing.com hu, 07 Mar 2024 08
- PBLA Forecast, Price Target & Analyst Ratings | PANBELA THERAPEUTICS INC (NASDAQ:PBLA) - ChartMill Sun, 14 Feb 2021 12
- Panbela Announces Closing of Approximately $8.5 Million Public Offering - Yahoo Finance Wed, 21 Jun 2023 07
- What is the current Price Target and Forecast for Panbela Therapeutics Inc. (PBLA) - Zacks Investment Research Wed, 12 Apr 2023 14
- Why Is Aclarion (ACON) Stock Down 16% Today? - InvestorPlace Mon, 29 Jan 2024 08
- PBLA Price History for Panbela Therapeutics Stock - Barchart.com Wed, 17 Mar 2021 10
- Panbela Therapeutics Inc. (PBLA) Share Price Today | Panbela Therapeutics (PBLA) Live NSE/BSE - Value Research Fri, 03 Jun 2022 13
- Panbela shares downgraded on cash and listing risks - Investing.com hu, 16 May 2024 07
- Panbela Announces Transfer to OTCQB Market - GlobeNewswire ue, 16 Apr 2024 07
- PBLA Panbela Therapeutics (NASDAQ) up 509900.00% intraday 07 Apr 2026: watch volume and liquidity - Meyka ue, 07 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
25.65
-24.77%
|
34.09
+240.59%
|
10.01
|
| Research And Development |
|
20.61
-26.51%
|
28.05
+417.22%
|
5.42
|
| Selling General And Administration |
|
5.03
-16.73%
|
6.04
+31.76%
|
4.59
|
| General And Administrative Expense |
|
5.03
-16.73%
|
6.04
+31.76%
|
4.59
|
| Other Gand A |
|
5.03
-16.73%
|
6.04
+31.76%
|
4.59
|
| Total Expenses |
|
25.65
-24.77%
|
34.09
+240.59%
|
10.01
|
| Operating Income |
|
-25.65
+24.77%
|
-34.09
-240.59%
|
-10.01
|
| Total Operating Income As Reported |
|
-25.65
+24.77%
|
-34.09
-240.59%
|
-10.01
|
| EBITDA |
|
-25.13
+27.70%
|
-34.76
-227.59%
|
-10.61
|
| Normalized EBITDA |
|
-25.53
+26.55%
|
-34.76
-227.59%
|
-10.61
|
| EBIT |
|
-25.13
+27.70%
|
-34.76
-227.59%
|
-10.61
|
| Total Unusual Items |
|
0.40
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.40
|
0.00
|
0.00
|
| Special Income Charges |
|
0.40
|
0.00
|
0.00
|
| Net Income |
|
-25.26
+27.68%
|
-34.93
-244.68%
|
-10.13
|
| Pretax Income |
|
-25.45
+27.39%
|
-35.05
-229.94%
|
-10.62
|
| Net Non Operating Interest Income Expense |
|
-0.19
+29.20%
|
-0.27
-2390.91%
|
-0.01
|
| Interest Expense Non Operating |
|
0.32
+10.07%
|
0.29
+2300.00%
|
0.01
|
| Net Interest Income |
|
-0.19
+29.20%
|
-0.27
-2390.91%
|
-0.01
|
| Interest Expense |
|
0.32
+10.07%
|
0.29
+2300.00%
|
0.01
|
| Interest Income Non Operating |
|
0.12
+778.57%
|
0.01
+1300.00%
|
0.00
|
| Interest Income |
|
0.12
+778.57%
|
0.01
+1300.00%
|
0.00
|
| Other Income Expense |
|
0.39
+157.48%
|
-0.68
-13.29%
|
-0.60
|
| Other Non Operating Income Expenses |
|
-0.01
+98.83%
|
-0.68
-13.29%
|
-0.60
|
| Tax Provision |
|
-0.19
-60.34%
|
-0.12
+76.23%
|
-0.49
|
| Tax Rate For Calcs |
|
0.00
+124.24%
|
0.00
-89.35%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-25.26
+27.68%
|
-34.93
-244.68%
|
-10.13
|
| Net Income From Continuing Operation Net Minority Interest |
|
-25.26
+27.68%
|
-34.93
-244.68%
|
-10.13
|
| Net Income From Continuing And Discontinued Operation |
|
-25.26
+27.68%
|
-34.93
-244.68%
|
-10.13
|
| Net Income Continuous Operations |
|
-25.26
+27.68%
|
-34.93
-244.68%
|
-10.13
|
| Normalized Income |
|
-25.66
+26.54%
|
-34.93
-244.68%
|
-10.13
|
| Net Income Common Stockholders |
|
-25.26
+27.68%
|
-34.93
-244.68%
|
-10.13
|
| Diluted EPS |
|
-316.52
+98.42%
|
-19,973.13
-10.36%
|
-18,098.21
|
| Basic EPS |
|
-316.52
+98.42%
|
-19,973.13
-10.36%
|
-18,098.21
|
| Basic Average Shares |
|
0.11
+6114.47%
|
0.00
+212.32%
|
0.00
|
| Diluted Average Shares |
|
0.11
+6114.47%
|
0.00
+212.32%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-25.26
+27.68%
|
-34.93
-244.68%
|
-10.13
|
| Gain On Sale Of PPE |
|
0.40
|
0.00
|
—
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
11.80
|
| Current Assets |
|
3.06
|
| Cash Cash Equivalents And Short Term Investments |
|
2.58
|
| Cash And Cash Equivalents |
|
2.58
|
| Receivables |
|
0.18
|
| Taxes Receivable |
|
0.18
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
0.30
|
| Total Non Current Assets |
|
8.74
|
| Non Current Prepaid Assets |
|
8.74
|
| Other Non Current Assets |
|
—
|
| Total Liabilities Net Minority Interest |
|
16.51
|
| Current Liabilities |
|
12.32
|
| Payables And Accrued Expenses |
|
10.80
|
| Payables |
|
9.94
|
| Accounts Payable |
|
9.94
|
| Current Accrued Expenses |
|
0.86
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.52
|
| Current Debt And Capital Lease Obligation |
|
1.00
|
| Current Debt |
|
1.00
|
| Other Current Borrowings |
|
1.00
|
| Total Non Current Liabilities Net Minority Interest |
|
4.19
|
| Long Term Debt And Capital Lease Obligation |
|
4.19
|
| Long Term Debt |
|
4.19
|
| Stockholders Equity |
|
-4.71
|
| Common Stock Equity |
|
-4.71
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.48
|
| Ordinary Shares Number |
|
0.48
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
120.04
|
| Retained Earnings |
|
-125.50
|
| Gains Losses Not Affecting Retained Earnings |
|
0.74
|
| Treasury Stock |
|
0.00
|
| Other Equity Adjustments |
|
0.74
|
| Total Equity Gross Minority Interest |
|
-4.71
|
| Total Capitalization |
|
-0.52
|
| Working Capital |
|
-9.26
|
| Invested Capital |
|
0.48
|
| Total Debt |
|
5.19
|
| Net Debt |
|
2.62
|
| Net Tangible Assets |
|
-4.71
|
| Tangible Book Value |
|
-4.71
|
| Current Notes Payable |
|
0.00
|
| Interest Payable |
|
0.24
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow |
|
-25.25
-65.29%
|
-15.28
-110.85%
|
-7.25
|
| Cash Flow From Continuing Operating Activities |
|
-25.25
-65.29%
|
-15.28
-110.85%
|
-7.25
|
| Net Income From Continuing Operations |
|
-25.26
+27.68%
|
-34.93
-244.68%
|
-10.13
|
| Other Non Cash Items |
|
0.24
-12.82%
|
0.27
|
—
|
| Stock Based Compensation |
|
0.82
-24.36%
|
1.09
-15.46%
|
1.29
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
17.74
|
0.00
|
| Operating Gains Losses |
|
-0.40
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
-0.40
|
0.00
|
—
|
| Change In Working Capital |
|
-0.65
-215.74%
|
0.56
-65.13%
|
1.60
|
| Change In Receivables |
|
-0.13
-162.26%
|
0.21
+315.69%
|
0.05
|
| Change In Prepaid Assets |
|
-5.40
-100.74%
|
-2.69
-817.41%
|
-0.29
|
| Change In Payables And Accrued Expense |
|
4.88
+60.82%
|
3.04
+64.50%
|
1.84
|
| Change In Accrued Expense |
|
-2.18
-377.23%
|
0.79
-35.26%
|
1.21
|
| Change In Payable |
|
7.06
+213.92%
|
2.25
+256.42%
|
0.63
|
| Change In Account Payable |
|
7.06
+213.92%
|
2.25
+256.42%
|
0.63
|
| Investing Cash Flow |
|
0.40
+160.98%
|
-0.66
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
0.40
+160.98%
|
-0.66
|
0.00
|
| Capital Expenditure |
|
—
|
-0.66
|
—
|
| Net Business Purchase And Sale |
|
0.00
-100.00%
|
0.00
|
0.00
|
| Net Intangibles Purchase And Sale |
|
0.40
+160.61%
|
-0.66
|
0.00
|
| Purchase Of Intangibles |
|
0.00
+100.00%
|
-0.66
|
0.00
|
| Net Other Investing Changes |
|
—
|
—
|
-0.54
|
| Financing Cash Flow |
|
26.14
+388.27%
|
5.35
-46.97%
|
10.10
|
| Cash Flow From Continuing Financing Activities |
|
26.14
+388.27%
|
5.35
-46.97%
|
10.10
|
| Net Issuance Payments Of Debt |
|
-1.65
|
0.00
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
-1.65
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
|
| Short Term Debt Payments |
|
-1.65
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
-1.65
|
0.00
|
—
|
| Net Common Stock Issuance |
|
23.04
+330.79%
|
5.35
-40.92%
|
9.05
|
| Common Stock Payments |
|
-0.01
|
—
|
—
|
| Repurchase Of Capital Stock |
|
-0.01
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
4.75
+94880.00%
|
0.01
-99.52%
|
1.04
|
| Changes In Cash |
|
1.29
+112.22%
|
-10.58
-471.03%
|
2.85
|
| Effect Of Exchange Rate Changes |
|
0.00
+100.00%
|
-0.00
+33.33%
|
-0.01
|
| Beginning Cash Position |
|
1.28
-89.17%
|
11.87
+31.53%
|
9.02
|
| End Cash Position |
|
2.58
+100.62%
|
1.28
-89.17%
|
11.87
|
| Free Cash Flow |
|
-25.25
-58.44%
|
-15.94
-119.96%
|
-7.25
|
| Interest Paid Supplemental Data |
|
0.40
+2593.33%
|
0.01
+25.00%
|
0.01
|
| Common Stock Issuance |
|
23.05
+330.98%
|
5.35
-40.92%
|
9.05
|
| Issuance Of Capital Stock |
|
23.05
+330.98%
|
5.35
-40.92%
|
9.05
|
| Sale Of Business |
|
0.00
-100.00%
|
0.00
|
0.00
|
| Sale Of Intangibles |
|
0.40
|
0.00
|
—
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|